Current trends and future prospects of drug repositioning in gastrointestinal oncology

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 4, 2024

Gastrointestinal (GI) cancers comprise a significant number of cancer cases worldwide and contribute to high percentage cancer-related deaths. To improve survival rates GI patients, it is important find implement more effective therapeutic strategies with better prognoses fewer side effects. The development new drugs can be lengthy expensive process, often involving clinical trials that may fail in the early stages. One strategy address these challenges drug repurposing (DR). Drug developmental involves using existing approved for other diseases leveraging their safety pharmacological data explore potential use treating different diseases. In this paper, we outline associated DR as promising alternative approach. We have presented an extensive review methodologies, research efforts examples repurposed within various types, such colorectal, pancreatic liver cancers. Our aim provide comprehensive overview employing approach inform future endeavors field.

Language: Английский

The Effects of Nebivolol-Gefitinib-Loratadine Against Lung Cancer Cell Lines

In Vivo, Journal Year: 2024, Volume and Issue: 38(6), P. 2688 - 2695

Published: Oct. 29, 2024

Background/Aim: Non-small-cell lung cancer (NSCLC) is the most frequently diagnosed malignancy and first cause of cancer-related death. Thus, finding alternative therapeutic options crucial. Drug repurposing offers in a simplified affordable manner, especially to patients developing countries. Several drugs including antihistamines beta-adrenergic receptor blockers (beta-blockers) display antiproliferative properties on cells. Interestingly, NSCLC who had used either or beta-blockers showed improved response chemotherapy reduced mortality comparison non-users any these drugs. However, combination therapy gaining substantial interest many cancers non-EGFR mutated NSCLC. Here, we investigated antineoplastic effect antihistamine loratadine, beta-blocker nebivolol, tyrosine-kinase inhibitor gefitinib cell lines. Materials Methods: A-549 NCI-H1975 lines were used. The gefitinib, loratadine metabolic activity was studied using MTT assay. inhibitory concentrations (IC₂₀ IC₅₀) calculated drug-combination experiments. Apoptosis flow cytometry; survival colony formation Results: nebivolol-loratadine-gefitinib produced significant synergistic inhibiting formation, as well promoting apoptosis both Noteworthy, line carrying EGFR mutation (NCI-H1975) very similar that does not exhibit such (A-549 cells). Conclusion: nebivolol-gefitinib-loratadine may be promising for treatment.

Language: Английский

STADS: Spatial Transcriptomics to Aid Drug-reposition Recommendation

2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM), Journal Year: 2023, Volume and Issue: unknown, P. 2737 - 2740

Published: Dec. 5, 2023

Drug repurposing is a promising strategy to find new usage for existing drugs outside of their original purpose. We have recently developed computational framework ASGARD that employs single cell RNA-sequencing (scRNA-seq) repurpose drugs. However, scRNA-seq lacks the spatial information tissue, an important determinant heterogeneity within tissue micro-environment. In this paper, we propose Spatial Transcriptomics Aid Drug-reposition Recommendation (STADS) framework, drug (ST) datasets with gene expression in situ. STADS reduces ST by spatially-aware embedding, integrates multiple healthy and diseased samples, identifies matched domains between disease controls, then repurposes novel score considers differentially expressed genes control samples among all domains. apply dataset patients Hepatocellular Carcinoma demonstrate its superior performance ASGARD. personalized prediction method using data.

Language: Английский